The article explores the favorable impact of apabetalone treatment on kidney cells and its implications for the prevention of negative cardiovascular outcomes in people suffering from chronic kidney disease (CKD).
Publication Highlights Include: Loss of kidney function is an independent risk factor for cardiovascular disease, as cardiovascular events are the leading cause of death in CKD patients
In the phase 3 BETonMACE trial, apabetalone reduced risk of major adverse cardiac events (MACE) by an extraordinary 50% among participants with reduced kidney function
In this study, activated human kidney cells were treated with apabetalone to investigate its impact on disease associated pathways and processes
Apabetalone treatment suppressed the expression of key drivers of fibrosis, inflammation, and calcification, all of which contribute to development and progression of CKD, and negatively impact the kidney-heart axis
These findings were confirmed by proteomic analysis of blood samples taken from CKD patients treated with apabetalone
'We saw, in BETonMACE, that apabetalone treatment improved cardiovascular outcomes in patients with reduced kidney function.' said Dr.
Additionally,
About Apabetalone
Apabetalone (RVX-208), is a first-in-class, small molecule, therapeutic candidate with an epigenetic mechanism of action. It is a BD2 (bromodomain) selective
Due to the extensive role for
Cardiology
Apabetalone is the first therapy of its kind to receive Breakthrough Therapy Designation from the
About
Founded in 2001,
The Company's clinical program is focused on evaluating the lead epigenetic candidate apabetalone for the treatment of cardiovascular disease and associated comorbidities, and post COVID-19 conditions.
Forward Looking Statements
This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words 'believes', 'anticipates', 'plans', 'intends', 'will', 'should', 'expects', 'continue', 'estimate', 'forecasts', and other similar expressions. In particular, this news release includes forward looking information related to the potential role of apabetalone in the treatment of patients with cardiovascular disease, chronic kidney disease, COVID-19, post COVID-19 conditions, associated comorbidities, and other chronic diseases. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including those discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR at www.sedar.com. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Contact:
Email: ir@resverlogix.com
Tel: 403-254-9252
Web: www.resverlogix.com
(C) 2023 Electronic News Publishing, source